Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts have given Compass Therapeutics a consensus rating of Moderate Buy from 14 firms (11 buy, 1 strong buy, 1 hold, 1 sell) with an average 12‑month price target of $13.60.
• Institutional investors own 68.43% of the stock and several funds recently added shares, while CMPX trades near $1.85 (52‑week range $1.61–$6.88) and the company reports negative earnings (last quarter EPS -$0.10; FY forecast -0.44).
• Compass is a clinical‑stage immuno‑oncology company advancing monoclonal antibody programs including lead candidates CTX‑471 (PD‑1/PD‑L1 bispecific) and DSP107 (CD47‑SIRPα modulator).

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $13.60.

A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Monday, April 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Compass Therapeutics in a research note on Thursday, March 12th. Canaccord Genuity Group cut their price target on Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a research note on Tuesday, April 28th. Craig Hallum assumed coverage on Compass Therapeutics in a research note on Friday, February 13th. They issued a "buy" rating and a $15.00 price target for the company. Finally, D. Boral Capital reissued a "buy" rating and set a $30.00 price objective on shares of Compass Therapeutics in a report on Monday, April 27th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. LPL Financial LLC boosted its holdings in shares of Compass Therapeutics by 4.7% during the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company's stock valued at $239,000 after purchasing an additional 2,000 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after acquiring an additional 2,164 shares during the period. Focus Partners Wealth boosted its holdings in Compass Therapeutics by 16.2% during the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company's stock valued at $56,000 after acquiring an additional 2,206 shares during the period. Invesco Ltd. boosted its holdings in Compass Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company's stock valued at $343,000 after acquiring an additional 3,245 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Compass Therapeutics by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company's stock valued at $619,000 after acquiring an additional 3,329 shares during the period. Institutional investors own 68.43% of the company's stock.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $1.85 on Thursday. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The firm has a market capitalization of $332.26 million, a PE ratio of -4.50 and a beta of 0.79. The stock has a fifty day simple moving average of $5.02 and a two-hundred day simple moving average of $5.19.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). On average, sell-side analysts forecast that Compass Therapeutics will post -0.44 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.